HC Wainwright Analysts Increase Earnings Estimates for JBIO

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Jade Biosciences to a loss of $0.57 per share from a previous estimate of $0.63, while maintaining a Buy rating and $55 price target.
• Jade Biosciences reported a quarterly loss of $0.76 per share, missing the analyst consensus estimate of a $0.66 loss by $0.10.
• Analyst sentiment remains generally positive, with the stock carrying a consensus “Moderate Buy” rating and a $51.75 average price target; shares recently opened at $23.21.

Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report) - Investment analysts at HC Wainwright upped their Q3 2026 EPS estimates for Jade Biosciences in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst A. He now anticipates that the company will earn ($0.57) per share for the quarter, up from their previous estimate of ($0.63). HC Wainwright has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for Jade Biosciences' current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Jade Biosciences' Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($2.41) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at ($0.54) EPS, Q3 2027 earnings at ($0.55) EPS, Q4 2027 earnings at ($0.56) EPS, FY2027 earnings at ($2.19) EPS, FY2028 earnings at ($2.29) EPS, FY2029 earnings at ($2.33) EPS and FY2030 earnings at ($1.81) EPS.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.10).

A number of other equities analysts also recently weighed in on JBIO. Piper Sandler set a $55.00 price target on Jade Biosciences in a research report on Tuesday, June 2nd. Wall Street Zen cut Jade Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. BTIG Research boosted their target price on Jade Biosciences from $74.00 to $77.00 and gave the stock a "buy" rating in a report on Monday. Wedbush increased their price target on Jade Biosciences from $45.00 to $47.00 and gave the company an "outperform" rating in a research note on Monday. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $48.00 target price on shares of Jade Biosciences in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Jade Biosciences has a consensus rating of "Moderate Buy" and a consensus price target of $51.75.

Jade Biosciences Stock Performance

Shares of JBIO stock opened at $23.21 on Thursday. The firm's 50-day moving average is $19.95 and its 200-day moving average is $18.66. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -12.09 and a beta of 1.49. Jade Biosciences has a 52-week low of $6.67 and a 52-week high of $28.00.

Institutional Investors Weigh In On Jade Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new stake in shares of Jade Biosciences in the second quarter valued at about $154,000. Legal & General Group Plc bought a new position in Jade Biosciences during the second quarter worth about $29,000. Rhumbline Advisers acquired a new stake in Jade Biosciences in the 2nd quarter worth about $445,000. Russell Investments Group Ltd. acquired a new stake in Jade Biosciences in the 2nd quarter worth about $31,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Jade Biosciences in the 2nd quarter worth about $114,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source